Circulating tumor cell eradication as an intermediate efficacy end point for metastatic castration-resistant prostate cancer: Is there enough evidence?

Emmanuel S. Antonarakis

doi:10.1200/JCO.2017.76.5487

Circulating tumor cell eradication as an intermediate efficacy end point for metastatic castration-resistant prostate cancer: Is there enough evidence?

Emmanuel S. Antonarakis

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	525-527
Number of pages	3
Journal	Journal of Clinical Oncology
Volume	36
Issue number	6
DOIs	https://doi.org/10.1200/JCO.2017.76.5487
State	Published - Feb 20 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher link

10.1200/JCO.2017.76.5487

Find It

Find It at U of M Libraries

Cite this

@article{e84d3bc7c8504bb69a67d34a46fef384,

title = "Circulating tumor cell eradication as an intermediate efficacy end point for metastatic castration-resistant prostate cancer: Is there enough evidence?",

author = "Antonarakis, \{Emmanuel S.\}",

year = "2018",

month = feb,

day = "20",

doi = "10.1200/JCO.2017.76.5487",

language = "English (US)",

volume = "36",

pages = "525--527",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - Circulating tumor cell eradication as an intermediate efficacy end point for metastatic castration-resistant prostate cancer

T2 - Is there enough evidence?

AU - Antonarakis, Emmanuel S.

PY - 2018/2/20

Y1 - 2018/2/20

UR - https://www.scopus.com/pages/publications/85042072038

UR - https://www.scopus.com/pages/publications/85042072038#tab=citedBy

U2 - 10.1200/JCO.2017.76.5487

DO - 10.1200/JCO.2017.76.5487

M3 - Editorial

C2 - 29272163

AN - SCOPUS:85042072038

SN - 0732-183X

VL - 36

SP - 525

EP - 527

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 6

ER -

Circulating tumor cell eradication as an intermediate efficacy end point for metastatic castration-resistant prostate cancer: Is there enough evidence?

UN SDGs

Publisher link

Find It

Other files and links

Cite this